One case of severe hepatotoxicity caused by fulzerasib tables

doi:10.19803/j.1672-8629.20260143

Abstract

Abstract: Objective To investigate the risk factors, potential mechanisms and therapeutic strategies related to drug-induced liver injury (DILI) caused by fulzerasib tablets so as to provide references for safe clinical medication. Methods One case of advanced non-small cell lung cancer treated with fulzerasib tablets was analyzed, DILI induced by targeted drugs was identified, and the pathogenesis and targeted therapeutic strategies were explored. Results The patient developed severe cholestatic DILI after treatment with fulzerasib tablets. Causality assessment suggested the association with fulzerasib was “probable”. After drug discontinuation and hepatoprotective and cholagogic treatment, the patient’s indicators of liver function were significantly improved. Conclusion Risk factors for hepatotoxicity during clinical use of antineoplastic drugs deserve attention. In case of adverse reactions of DILI, quick drug withdrawal and symptomatic treatment are critical.

Key words: Fulzerasib Tablets, Targeted Therapy, Non-Small Cell Lung Cancer, Cholestatic, Drug-Induced Liver Injury(DILI), Hepatotoxicity, Adverse Drug Reaction

CLC Number:

R994.11

Jiang Wei, Hou Kaifeng, Xu Lei, Ding Li, Xu Yingying, Ge Hailin, Wang Junping, Jiang Jiemei. One case of severe hepatotoxicity caused by fulzerasib tables[J]. Chinese Journal of Pharmacovigilance, 2026, 23(7): 826-828.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20260143

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I7/826

References

[1] Wang M, Herbst R S, Boshoff C.Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med, 2021, 27(8):1345-1356.
[2] Nussinov R, Tsai C J, Jang H.Anticancer drug resistance: an update and perspective[J]. Drug Resist Updat,2021, 59: 100796.
[3] Makarem M, Jänne P A.Top advances of the year: targeted therapy for lung cancer[J]. Cancer, 2024, 130(19): 3239-3250.
[4] Lamb Y N.Correction: fulzerasib: first approval[J]. Drugs, 2025, 85(2): 281.
[5] He Fei.Conditional approval of fluzelesen for marketing by the National Medical Products Administration[J]. Medicine & People(药物与人), 2024(9): 24-25.
[6] Björnsson H K, Björnsson E S.Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management[J]. Eur J Intern Med, 2022, 97: 26-31.
[7] Gudd C L C, Sheth R, Thursz M R, et al. Immune checkpoint inhibitor-induced liver injury[J]. Semin Liver Dis, 2023, 43(4): 402-417.
[8] Wang GuanJie, Du ShiFang, Liu BaoSheng, et al. Analysis of 107 adverse reaction reports of drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(3): 331-333, 338.
[9] Yang Biqian, He Huiming, Yin Tingmei, et al.Study on the mechanism of N-acetylcysteine in alleviating cisplatin-induced liver injury[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2025, 50(6): 815-820.
[10] Huang Bei, Xia Xiaojian, Sun Qiwu, et al.Medication analysis of drug-induced liver injury in a patient with non-small cell lung cancer[J]. Central South Pharmacy(中南药学), 2017, 15(10): 1494-1498.
[11] Luo J, Florez N, Donnelly A, et al.Adagrasib treatment after sotorasib-related hepatotoxicity in patients with kras g12c-mutated non-small cell lung cancer: a case series and literature review[J]. JCO Precis Oncol, 2024 , 8: e2400255.
[12] Ma Shiwu, Liu Chenghai, Liu Xiaoyan, et al.Guidelines for the diagnosis and treatment of drug-induced liver injury in China (2023 edition)[J]. Chinese Journal of Gastroenterology(胃肠病学), 2023, 28(7): 397-431.
[13] Liu S, Wang J.Recent progress of Glutathione peroxidase 4 inhibitors in cancer therapy[J]. Mini Rev Med Chem, 2025, 25(1): 42-57.
[14] Zhou Q, Meng X, Sun L, et al.Efficacy and safety of KRASG12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study[J]. J Thorac Oncol, 2024, 19(12): 1630-1639.
[15] Wang S, Lin W, Ahmed B, et al.Study of the mass balance, biotrans-formation, and safety of [¹⁴C] IBI351 in healthy Chinese subjects[J]. J Biomed Res, 2024, 39(4): 382-393.
[16] Hibino M, Maeki M, Tokeshi M, et al.A system that delivers an antioxidant to mitochondria for the treatment of drug-induced liver injury[J]. Sci Rep, 2023, 13(1): 6961.